Lack of Immune Response to Differentiated Cells Derived from Syngeneic Induced Pluripotent Stem Cells  by Guha, Prajna et al.
Cell Stem Cell
Brief ReportLack of Immune Response to Differentiated Cells
Derived from Syngeneic
Induced Pluripotent Stem Cells
Prajna Guha,1 John W. Morgan,1 Gustavo Mostoslavsky,2 Neil P. Rodrigues,1,2,3,4 and Ashleigh S. Boyd1,2,3,4,*
1NIH Center of Biomedical Research Excellence (COBRE) in Stem Cell Biology, Roger Williams Medical Center, Boston University School of
Medicine, Providence, RI 02908, USA
2Center for Regenerative Medicine (CReM)
3Department of Dermatology
Boston University School of Medicine, Boston, MA 02118, USA
4These authors contributed equally to this work
*Correspondence: asboyd@bu.edu
http://dx.doi.org/10.1016/j.stem.2013.01.006SUMMARY
The prospects for using autologous induced pluripo-
tent stem cells (iPSCs) in cell replacement therapy
have been tempered by evidence that undifferenti-
ated, syngeneic mouse iPSCs are immunogenic
upon transplantation. However, the immunogenicity
of more therapeutically relevant differentiated cells
remains unexplored. Here, we differentiated mouse
iPSCs into embryoid bodies (EBs) or representative
cell types spanning the three embryonic germ layers
and assessed their immunogenicity in vitro and after
their transplantation into syngeneic recipients. We
found no evidence of increased T cell proliferation
in vitro, rejection of syngeneic iPSC-derived EBs/
tissue-specific cells (TSCs) after transplantation, or
an antigen-specific secondary immune response.
Thus, differentiated cells derived from syngeneic
iPSCs do not appear to be rejected after transplanta-
tion. We also found little evidence of an immune
response to undifferentiated, syngeneic iPSCs.
Our data support the idea that differentiated cells
generated from autologous iPSCs could be applied
for cell replacement therapy without eliciting immune
rejection.Using the fully differentiated progeny of autologous inducedpluripotent stem cells (iPSCs) for cell replacement therapy
(CRT) to repair diseased tissues should hypothetically be
possible without immune rejection or the requirement for immu-
nosuppression to evade immune rejection (Boyd et al., 2012;
Tabar et al., 2008). This notion was questioned after the inaus-
picious finding that undifferentiated, genetically identical
(syngeneic) mouse iPSCs were immunogenic and rejected
upon transplantation (Zhao et al., 2011). This result was in accord
with another report showing immune rejection of major histo-
compatibility complex (MHC) matched, undifferentiated mouse
embryonic stem cells (ESCs) generated by parthenogenesis
(Kim et al., 2007). Yet embryoid bodies (EBs) differentiatedfrom these ESCs were accepted upon transplantation into
immunocompetent MHC-matched mice. Whether the differenti-
ated progeny of syngeneic iPSCs will similarly be accepted after
transplantation remains unclear. This matter is of substantial
relevance when considering the patient-specific utility of iPSCs
because only differentiated tissues derived from iPSCs will be
used in autologous CRT (Boyd et al., 2012; Yamanaka, 2012).
In this report, we differentiated syngeneic iPSCs into EBs or
representative cell types (endothelial cells, hepatocytes, and
neuronal cells) spanning the three embryonic germ layers and
assessed their immunogenicity in vitro and after transplantation
into syngeneic recipients.
We used an ESC line derived from C57BL/6 mice (hereafter
B6) (Brook and Gardner, 1997) and three B6 iPSC lines derived
by two different methods. With a lentiviral vector that expresses
Oct4, Klf4, Sox2, and cMyc in a single cassette (construct
scheme, Figure S1A, available online) (Sommer et al., 2009),
we generated two iPSC lines (iPS1 and iPS2) from tail tip
fibroblasts, which were karyotypically normal (Figure S1B), that
expressed pluripotency genes and markers (Figures S1C and
S1D) and gave rise to teratomas composed of tissues of the
three embryonic germ layers when transplanted into syngeneic
mice (Figures S1E and S1F). Given that viral integration may be
a determinant of immunogenicity in iPSCs (Boyd et al., 2012),
our experiments also included a previously characterized,
episomally derived iPSC line (Epi) that lacks viral integration
(Zhao et al., 2011).
Postulating that differentiated cells from each embryonic germ
layer represent diverse immunological targets, we conducted
our experiments using iPSC or ESC lines differentiated into cell
types from each of the germ layers: endothelial cells (meso-
derm), hepatocytes (endoderm), and neuronal cells (ectoderm)
(Figure 1A) (Abranches et al., 2009; Christodoulou et al., 2011;
Huang et al., 2010; Pruszak et al., 2009; Qiu et al., 2011). These
tissue-specific cells (TSCs) were characterized by assessing
typical gene expression (Figure 1B) and by using immunofluores-
cence microscopy (Figure 1C) to discern characteristic markers
of endothelial cells (VE-Cadherin, PECAM, Endoglin, and Tie-2),
hepatocytes (CD24, alpha-fetoprotein and albumin), and neu-
ronal cells (Otx-2, Sox2, and Nestin). To verify that TSCs were
specifically targeted toward one particular developmental
lineage, we also examined each collection of tissue-specificCell Stem Cell 12, 407–412, April 4, 2013 ª2013 Elsevier Inc. 407
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Figure 1. Differentiated Cells Derived from Syngeneic iPSCs Lack Immunogenicity In Vitro
(A) Micrographs are representative of endothelial cells, hepatocytes, and neuronal cells differentiated from either the B6 embryonic stem cell (ES) line, STEMCCA-
generated induced pluripotent stem cell lines (iPS), or the episomal iPSC line (Epi).
(B) RNA prepared from each of the differentiated cell types (endothelial cells, hepatocytes, and neuronal cells) was subjected to reverse transcriptase reaction
and qPCRwas performed for markers of endothelial cells (top panel), hepatocytes (middle panel), and neuronal cells (bottom panel), respectively (n = 3 separate
experiments per cell line). Results were normalized to GAPDH. Untreated cells were used as a control. Triplicates were used for each PCR. Error bars represent ±
SEM. *p < 0.05.
(C) Representative immunofluorescence staining with respective tissue-specific markers. Top two rows: endothelial cell grafts were stained for VE-Cadherin
(green) and PECAM (red). Middle two rows: hepatocyte grafts were stained for CD24 (green) and a-fetoprotein (AFP) (red). Bottom two rows: neuronal cell grafts
(legend continued on next page)
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Immunogenicity of iPSC Differentiated Cellsmarkers in the other cell types and found, for example, that hepa-
tocyte markers were not expressed by endothelial cells or
neuronal cells and vice versa (data not shown).
The immunogenicity of syngeneic iPSCs has previously been
associated with a specific gene expression pattern; Hormad,
Zg16, and Retn, were found to be overexpressed in rejecting
syngeneic iPSC teratoma grafts derived from transplanted undif-
ferentiated iPSCs (Zhao et al., 2011). However, when expression
of these genes was enforced in ESCs, only Zg16 and Hormad,
but not Retn, caused teratoma regression (Zhao et al., 2011).
We first examined expression of these genes throughout
in vitro differentiation in iPSC or ESC lines, in the undifferentiated
state (hereafter referred to as pluripotent stem cells: PSCs), in
partially differentiated EBs, and in TSCs (Figure 1D). Excepting
high expression of Hormad, Zg16, and Retn in partially differen-
tiated EBs derived from iPSCs and ESCs, low expression of
these genes was observed in PSCs and in TSCs derived from
them. Moreover, no significant difference was noted in expres-
sion of these genes between undifferentiated iPSCs and ESCs
or between PSCs and TSCs (Figure 1D).
Initial characterization of iPSC-derived differentiated cells
in vitro suggested that they may be capable of stimulating
T cell proliferation because theywere found to express low levels
of the costimulatory molecules CD80, CD86, and CD40 and
class I MHCby using flow cytometry (data not shown). To assess
whether iPSCs and cells derived from them could functionally
induce syngeneic T cell proliferation, we examined the prolife-
ration of CFSE-labeled CD4+ or CD8+ T cells (responders) iso-
lated from the spleens of syngeneic (B6) or allogeneic CBA
mice after in vitro stimulation with PSCs, EBs, or TSCs
(stimulators). The cells were cocultured at a 1:2 (responder:
stimulator) ratio for 72 hr and the percentage of CFSElo (prolifer-
ating cells) and CFSEhi (nonproliferating cells) was quantified
by flow cytometry (Figure 1E). In the syngeneic setting, minimal
proliferation was characterized by maintenance of the CFSEhi
peak, corresponding to a negligible CD4+ or CD8+ T cell
response (Figures 1E and 1F). This lack of response to syngeneic
tissue was uniform across cell type and, notably, undifferenti-
ated iPSCs were equally devoid of a T cell response compared
with undifferentiated ESCs. As expected, allogeneic CD4+ and
CD8+ T cells were strongly stimulated to proliferate, with the
vast majority of T cells extinguishing CFSE expression (Figures
1E and 1F). Similar results were obtained by varying the
responder to stimulator ratios (data not shown). In toto, these
data demonstrate that undifferentiated, syngeneic iPSCs and
their progeny lack immunogenicity in vitro.were stained for Nestin (green) and g Tubulin (red). Data are representative of five i
grafts and 50 mm for neuronal cell grafts.
(D) Gene expression of putative immunogenic genes Hormad, Zg16, and Retn w
cells (Endo), hepatocytes (Hep), and neuronal cells (Neu) derived from ES, iPS1, iP
of three independent experiments. *p < 0.05.
(E) Experimental design for the CFSE-T cell proliferation assay using CD4+ and CD
fluorescent dye CFSE can be used to track a cell’s division history because it is eq
as detected by flow cytometry. CFSElo/ cells have undergone proliferation while
CD4+ or CD8+ T cells were used to evaluate the loss of CFSE dye signal.
(F) CFSE-T cell proliferation assay comparing the proliferation of CFSE-labeled CD
CBA (allogeneic) mice cocultured with PSCs, EBs, or tissue specific cells (TSCs) (
(CFSElo) was quantified and shown as ± SEM of triplicates of two independent e
See also Figure S1.To stringently assess the in vivo immunogenicity of the
differentiated progeny of iPSCs, we transplanted PSCs, EBs,
or TSCs into the subcapsular renal space of syngeneic or
allogeneic recipient mice and analyzed graft survival after
30 days. We selected the subcapsular renal space as the site
for transplantation because it permits TSCs to be properly
vascularized, which encourages their engraftment. This trans-
plant location offers the added advantage of permitting relatively
straightforward retrieval of TSC grafts for further experimental
analysis (Boyd andWood, 2010; Boyd et al., 2008). As predicted,
allogeneic PSCs, EBs, and TSCs were rejected after trans-
plantation (Table S1 available online). In sharp contrast to the
findings of Zhao et al. (2011), we observed teratoma formation
in 100% of recipients that received undifferentiated syngeneic
iPSCs (Table S1 and Figures S1E and S1F). Likewise, syngeneic
EBs generated from iPSCs or ESCs formed teratomas in 100%
of transplant recipients (Table S1 and data not shown). Survival
of iPSC- or ESC-derived TSCs was also observed in 100%
of syngeneic recipients (Table S1). Figure 2A shows tissue
sections of TSC-engrafted kidneys in the syngeneic setting
stained with hematoxylin and eosin; there was insufficient
graft tissue remaining for similar analysis in the allogeneic
setting. Persistence of syngeneic iPSC- or ESC-derived TSC
grafts was demonstrated by immunofluorescence staining for
lineage markers (Figure 2B). Thus, undifferentiated, syngeneic
iPSCs and differentiated cells derived from them are not rejected
after transplantation.
Our preliminary analysis of longer-term, 3 month, syngeneic
iPSC- or ESC-derived endothelial and hepatocyte tissue
grafts showed graft persistence and retention of expression of
lineage-specific markers without teratoma formation (data not
shown). These data argue against the possibility of chronic
immune rejection in the context of transplanting syngeneic
iPSC-derived TSCs, though we cannot completely exclude
the possibility of immune rejection via minor histocompatability
antigens (Boyd et al., 2012).
We went on to examine infiltration of CD4+ and CD8+ T cells
into PSC, EB, or TSC grafts (Figure 2C). We noted some CD4+
and CD8+ T cell infiltration in transplanted grafts from PSCs
and EBs in the syngeneic setting (data not shown). However,
no T cells were observed in association with syngeneic iPSC-
or ESC-derived TSC grafts, further endorsing the view that
TSCs derived from syngeneic iPSCs are not immunogenic
in vivo (Figure 2C). Since there was insufficient tissue remaining
from TSC-derived allografts, we examined T cell infiltration into
the kidney, proximal to the site of allograft transplantation, usingndependent experiments. Scale bar = 10 mm for endothelial cell and hepatocyte
as assessed in pluripotent stem cells (PSC), embryoid bodies (EB), endothelial
S2, and Epi cell lines, respectively. Data are represented as ± SEMof triplicates
8+ T cells isolated from spleens of B6 (syngeneic) or CBA (allogeneic) mice. The
ually distributed between daughter cells uponmitosis, resulting in loss of signal
maintenance of CFSE signal denotes nondividing cells. Only viable (Hoescht)
4+ and CD8+ T cells (responders, R) isolated from spleens of B6 (syngeneic) or
stimulators, S) at a 1:2 (R:S) ratio for 72 hr. The percentage of proliferating cells
xperiments.
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Figure 2. Differentiated Cells Derived from Syngeneic iPSCs Are Not Rejected In Vivo, nor Do They Induce Secondary T Cell Responses
(A) Representative H&E staining of endothelial cells (Endo), hepatocytes (Hep), and neuronal cells (Neu) engrafted into syngeneic B6 recipient mice. K and G
indicate kidney and graft, respectively.
(legend continued on next page)
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Immunogenicity of iPSC Differentiated Cellspodocin and sodium-glucose transport protein (SGLT) to mark
kidney tissue (Figure S2A) (Kanasaki et al., 2008; Vallon et al.,
2011). There was extensive CD4+ and CD8+ T cell infiltration in
the kidneys of TSC-transplanted allogeneic recipient mice,
presumably reflecting the remnants of an immune response
to allogeneic transplanted tissue. In contrast, no T cells were
observed in the kidneys of TSC-engrafted syngeneic recipients
(Figure S2B). These data demonstrate an absence of an adaptive
immune response to TSCs derived from syngeneic iPSCs.
To ascertain whether iPSC-derived cells could be susceptible
to secondary immune responses, we performed a secondary
T cell proliferation assay using splenic T cells isolated from
mice transplanted with PSCs, EBs, or TSCs. These antigen-
experienced T cells were labeled with CFSE, and their prolife-
rative response to coculture stimulation with freshly isolated
PSCs, EBs, or TSCswas assessed by flowcytometry (Figure 2D).
While a significant immune response was elicited in allogeneic
PSCs and iPSC/ESC-derived EBs and TSCs, there was only
a minimal secondary T cell response to syngeneic PSCs or
iPSC/ESC-derived EBs and TSCs (Figure 2D).
We next examined whether ex vivo isolated antigen-experi-
enced T cells could exact direct cell killing on PSCs, EBs, or
TSCs (Figure 2E). Using the Annexin-V (Ann-V)/Hoescht (Hst)
assay, cell death was analyzed after 72 hr of coculture of freshly
isolated PSCs, EBs, or TSCs with splenic CD4+ or CD8+ T cells
isolated from transplant recipients. By assessing the proportion
of iPSC- or ESC-derived cells that underwent early (Ann-V+Hst)
and late (Ann-V+Hst+) apoptosis in response to CD4+ or CD8+
T cells, we showed that undifferentiated, syngeneic iPSCs and
their progeny were not subject to killing by antigen-experienced
T cells (Figure 2E). Contrasting with this, allogeneic iPSC- or
ESC-derived cells underwent apoptosis, as a direct result of
coculture with antigen-experienced CD4+ or CD8+ T cells
(Figure 2E).
Finally, expression levels of Hormad, Zg16, and Retn genes
(Zhao et al., 2011) were examined in surviving syngeneic PSC,
EB, or TSC grafts (Figure 2F). Teratomas derived from trans-
planting undifferentiated iPSCs or ESCs exhibited comparable
low level expression of these genes. This contrasts with previous
findings where overexpression of Hormad, Zg16, and Retn
was found in regressing teratomas generated by transplantation
of undifferentiated iPSCs, but not ESCs (Zhao et al., 2011). Post-(B) Representative immunostaining of endothelial cells, hepatocytes, and neurona
markers. Top three rows: endothelial cell grafts stained with VE-Cadherin (green
(green) and a-fetoprotein (AFP) (red). Bottom three rows: neuronal grafts stained
(C) Syngeneic endothelial, hepatocyte, and neuronal cell grafts were stained fo
infiltration. To label the engrafted cells, endothelial cells were stainedwith VE-Cad
bar = 20 mm.
(D) CFSE-labeled CD4+ and CD8+ T cells (responders) isolated from spleens of B6
EBs, or TSCs were cocultured with freshly isolated PSCs, EBs, or TSCs (stimula
stimulated to proliferate, was quantified and shown as ± SEM of triplicates of tw
(E) Early and late-stage apoptosis of PSCs, EBs, and TSCs cocultured for 72 hr w
(allogeneic) mice engrafted 30 days previouslywith PSCs, EBs, or TSCswas exam
dyeHoechst and apoptotic marker Annexin V to determinewhether antigen-exper
early apoptosis are Annexin-V+ Hoescht and those undergoing late apoptosis are
of two experiments.
(F) Q-PCR for putative immunogenic genes Hormad, Zg16, and Retn was perform
separate experiments per group). Background expression of genes from sham-
receiving a graft. Results were normalized to GAPDH. Triplicates were used for e
See also Figures S1 and S2 and Table S1.transplant syngeneic EBs from iPSCs and ESCs expressed
markedly attenuated levels of these genes when compared to
their pretransplant levels. However, posttransplant expression
of these genes in syngeneic grafts was comparable indepen-
dently of whether the differentiated cells were generated from
iPSCs or ESCs. Of note, PSCs and TSCs derived from syngeneic
iPSCs and ESCs expressed these genes at a similar low level
to that of those that were pretransplant (Figure 1E). These
data jointly demonstrate that no physiologic correlation exists
between basal, endogenous expression of Hormad, Zg16, and
Retn and syngeneic graft survival in any experimental setting:
low level gene expression in PSCs and in TSCs did not cause
syngeneic recipients to reject their grafts, and partially differen-
tiated EBs, which express higher endogenous levels of these
genes, also survived when transplanted into syngeneic recipi-
ents (Figures 1E and 2F).
Our study was prompted by a recent finding of immune rejec-
tion of teratomas generated by transplanting undifferentiated,
syngeneic iPSCs (Zhao et al., 2011). However, our data differ
from that of Zhao et al. on a number of key points. First, we found
no difference in immunogenicity between syngeneic iPSCs and
ESCs in the undifferentiated state. It seems unlikely that this
discrepancy reflects differences between the pluripotent stem
cell lines used in each study because one iPSC line (Epi) was
the same as that used by Zhao et al. and the ESC line was
derived from the same pure, inbred mouse background as in
their study (C57BL/6). Second, we were unable to replicate the
moderate rate of immune rejection of teratomas formed from
transplanting undifferentiated iPSCs into syngeneic recipients.
Third, we observed some lymphocytic infiltration to teratomas
generated from transplantation of both undifferentiated, synge-
neic iPSCs and ESCs (as well as some infiltration into EBs
derived from them). This phenomenonmay be a result of immune
responses against residual pluripotent stem cell markers such as
Oct4 (Dhodapkar et al., 2010). Fourth, in contrast to Zhao et al.,
we found comparable, low-level expression of Hormad, Zg16,
and Retn between undifferentiated, syngeneic iPSCs and
ESCs in the posttransplant setting. The subcutaneous
transplant site used by Zhao et al. could in principle contribute
to the differences observed between our studies. However, the
subcapsular renal space transplant site used here, with its abun-
dant blood supply and thus access to immune cells, could ifl cells engrafted into syngeneic B6 recipient mice stained for tissue-specific cell
) and PECAM (red). Middle three rows: hepatocyte grafts stained with CD24
with Nestin (green) and g Tubulin (red). Scale bar = 50 mm.
r CD4 (green, top panel) or CD8 (green, bottom panel) to analyze T cell graft
herin (VCAD), hepatocyteswith CD24, and neuronal cells with CD29 (red). Scale
(syngeneic) or CBA (allogeneic) mice engrafted 30 days previously with PSCs,
tors) at a 1:2 (R:S) ratio for 72 hr. The percentage of CFSElo cells, having been
o experiments.
ith ex vivo isolated CD4+ or CD8+ T cells from spleens of B6 (syngeneic) or CBA
ined. After 72 hrs, PSCs, EBs, or TSCswere harvested and stainedwith the vital
ienced T cells would directly kill syngeneic iPSC-derived cells. Cells undergoing
Annexin-V+ Hoescht+. Data are represented asmean value ± SEMof triplicates
ed with RNA isolated from grafts of PSCs, EBs, or tissue-specific cells (n = 3
transplanted kidneys was subtracted from PCR results from those recipients
ach PCR. Error bars represent ± SEM.
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syngeneic iPSCs, which, as alluded to earlier, express low levels
of costimulatory molecules. Thus, we would argue that our
approach would have detected inherent immunogenicity of
syngeneic iPSCs if it had occurred. Overall, our results do not
support the idea that there is selective immunogenicity to
undifferentiated, syngeneic iPSCs.
In closing, we have formally defined the in vitro and in vivo
immunogenicity of differentiated cells from syngeneic iPSCs
using three mouse iPSC lines reprogrammed by two different
methods. In a clinically relevant model of CRT, we found little
indication of immunogenicity when iPSCs were differentiated
in vitro and transplanted into syngeneic recipients. Evidence
for a difference in the immunogenicity between the progeny of
syngeneic iPSCs and their ESC counterparts was also lacking,
making it improbable that the known genetic and epigenetic
abnormalities in iPSCs play a significant role in immunogenicity
in this context. So in what other clinical setting could autologous
iPSC immunogenicity be augmented? The facility to correct
monogenic diseases in a patient-specific manner by gene
therapy of iPSCs is a highly attractive therapeutic prospect
(Boyd et al., 2012; Yamanaka, 2012). However, even in
this apparently autologous setting, it is entirely possible that
differentiated cells from disease-corrected, gene modified
iPSCs will be rejected by the patient’s immune system (see
Boyd et al., 2012). This consideration aside, our results bode
well for the likelihood of using autologous iPSCs in CRT without
a requirement for immunosuppression.
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